AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11095321
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg once daily
Trial: 25100080
Drug: Rabeprazole 5
RxNorm normalized name: RABEprazole 5 mg oral delayed release capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 5 mg once daily
Trial: 25100080
Drug: Teprenone 50
RxNorm normalized name: teprenone
DrugBank: Teprenone (DB15955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprenone 50 mg three times per day (active control)
Trial: 22340282
Drug: ALA-PDT (20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-PDT (20% solution of ALA applied for 1 hour, two sessions)
Trial: 22340282
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (half a sachet applied twice weekly)
Trial: 12000378
Drug: Griseofulvin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin (20 mg x kg(‐1) x day(‐1)) for 12 weeks
Trial: 6802779
Drug: Phenobarbital (PB)
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (PB) at doses ranging from 0.5 to 1.5 mg/kg/day and from 1.6 to 2.5 mg/kg/day
Trial: 6802779
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of Phenobarbital (PB)
Trial: 31642352
Drug: High-dose exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exercise training (1-hour sessions, 3 times weekly for 12 weeks)
Trial: 31642352
Drug: Low-dose exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exercise training (1-hour sessions, 2 times weekly for 8 weeks)
Trial: 23945130
Drug: SP-IPT (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-IPT (25 mg of sulfadoxine and 1.25 mg of pyrimethamine)
Trial: 23945130
Drug: Daily co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily co-trimoxazole doses (960 mg per dose)
Trial: 16718797
Drug: One-day quadruple
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day quadruple therapy (omeprazole 20 mg, amoxicillin 1 g, furazolidone 200 mg, colloidal bismuth subcitrate 220 mg four times for one day)
Trial: 16718797
Drug: Seven-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-day triple therapy (omeprazole 40 mg, amoxycillin 1 g, furazolidone 100 mg, all twice a day for 7 days)
Trial: 11318078
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate ophthalmic gel-forming solution (timolol GS) once daily
Trial: 9542556
Drug: Epidural tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural tramadol 20 mg
Trial: 9542556
Drug: Epidural tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural tramadol 100 mg
Trial: 3581680
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atropine and pilocarpine
Trial: 29729169
Drug: Omacor (omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor (omega-3 polyunsaturated fatty acids) 2 capsules (1680 mg) for one month along with standard treatment
Trial: 27566551
Drug: Deep sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sea fish oil (0.2 ml/Kg bodyweight/day)
Trial: 27566551
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (0.2 ml/Kg bodyweight/day)
Trial: 26599957
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration (WBV) treatment
Trial: 15951544
Drug: Retarded release
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retarded release phosphatidylcholine (6 g daily for three months)
Trial: 7558547
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of living wills in the treatment group
Trial: 7558547
Drug: Preparation of
RxNorm normalized name: kit for the preparation of Ga-68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of living wills in the control group
Trial: 7558547
Drug: Life-sustaining treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-sustaining treatment decisions in the treatment group
Trial: 7558547
Drug: Life-sustaining treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-sustaining treatment decisions in the control group
Trial: 2198381
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg orally
Trial: 28101565
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation + conventional physical therapy
Trial: 28101565
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (sham neuromuscular electrical stimulation + conventional physical therapy)
Trial: 20718944
Drug: Δ(9) ‐THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ(9) ‐THC (10 mg in IBS patients, 5 and 10 mg in healthy volunteers)
Trial: 17096160
Drug: Hyperfractionation (Hfx)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionation (Hfx) RTx with concurrent TPF CTx
Trial: 17096160
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation (Cfx) RTx with concurrent TPF CTx
Trial: 15190136
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of droperidol
Trial: 11296071
Drug: Holistic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holistic medicine consultations for oncology patients
Trial: 11296071
Drug: Holistic medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holistic medicine consultations for symptom management
Trial: 11296071
Drug: Questions about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questions about specific therapies
Trial: 6751374
Drug: Oral beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral beta-carotene
Trial: 8157190
Drug: Cisplatin with
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin with 5-FU infusion (regimen B)
Trial: 8157190
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy with cisplatin
Trial: 17408818
Drug: Schwarz subcutaneous
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz subcutaneous
Trial: 17408818
Drug: Edmonston-Zagreb subcutaneous
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb subcutaneous
Trial: 15131566
Drug: Nebulized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized lidocaine (4%, 100 mg) 4 times daily for 8 weeks
Trial: 15131566
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) 4 times daily for 8 weeks
Trial: 11176555
Drug: Paper-and-pencil questionnaire
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil questionnaire administration
Trial: 11176555
Drug: Computer administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Computer administration
Trial: 3124478
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 and folic acid treatment for 3 months
Trial: 30880747
Drug: NACCRT (Neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NACCRT (Neoadjuvant Concurrent Chemoradiotherapy)
Trial: 28201598
Drug: TransCon GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon GH (0.14 mg GH/kg/wk)
Trial: 28201598
Drug: TransCon GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon GH (0.21 mg GH/kg/wk)
Trial: 28201598
Drug: TransCon GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon GH (0.30 mg GH/kg/wk)
Trial: 28201598
Drug: Genotropin (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin (0.03 mg GH/kg/d)
Trial: 19015206
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg every 4 weeks
Trial: 16080835
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg bid)
Trial: 12034158
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg bid)
Trial: 11913407
Drug: CE +
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE + MPA 2.5 mg
Trial: 11913407
Drug: CE +
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE + MPA 5 mg
Trial: 11913407
Drug: CE +
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE + MPA 5 mg (last 14 cycle days)
Trial: 11913407
Drug: CE +
RxNorm normalized name: Multimineral/Multivitamin Oral Tablet [ACE + Z]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE + MPA 10 mg (last 14 cycle days)
Trial: 15863547
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching tablets)
Trial: 7986853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without lipids, all caloric intake from hypertonic glucose solution)
Trial: 3142775
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg twice daily for 4 weeks)
Trial: 31150711
Drug: Topical ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules (DMR)
Trial: 17785705
Drug: Denosumab (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (30, 120, or 180 mg subcutaneously every 4 weeks; 60 or 180 mg every 12 weeks)
Trial: 8638357
Drug: Flutamide 125
RxNorm normalized name: flutamide 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 125 mg twice daily
Trial: 8638357
Drug: Flutamide 250
RxNorm normalized name: flutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 250 mg once daily
Trial: 8638357
Drug: Flutamide 250
RxNorm normalized name: flutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 250 mg twice daily
Trial: 8638357
Drug: Flutamide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (all doses)
Trial: 1602504
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 3.5 g ampicillin plus 1 g probenecid
Trial: 1602504
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ampicillin orally four times a day for 10 days
Trial: 24799159
Drug: Ketamine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine group (n = 31) received intravenous ketamine 1 mg/kg before incision, followed by 2 μg/kg/minute infusion for 72 hours plus sufentanil patient‐controlled intravenous analgesia after thoracotomy.
Trial: 24799159
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 47) received intravenous 0.9% normal saline and infusion plus sufentanil patient‐controlled intravenous analgesia.
Trial: 19080323
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus Endostar
Trial: 15767771
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole gel
Trial: 15767771
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2% ketoconazole and 0.05% desonide
Trial: 15767771
Drug: 0.05% desonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% desonide gel
Trial: 15767771
Drug: Vehicle (unmedicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (unmedicated gel)
Trial: 14666761
Drug: Yishen Jianpi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishen Jianpi Yangxue Tongli Therapy (YJYTT)
Trial: 6316420
Drug: 5.0 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 ng/kg/min PGI2 X Na infusion abruptly terminated
Trial: 6316420
Drug: 5.0 ng/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 ng/kg/min PGI2 X Na infusion tapered off over 12 hrs
Trial: 15863468
Drug: Probiotic (1x10(9)Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (1x10(9)Lactobacillus fermentum VRI‐033 PCC; Probiomics), twice daily for 8 weeks
Trial: 15863468
Drug: Placebo, equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, equivalent volume, twice daily for 8 weeks
Trial: 10802909
Drug: Nutrient supplements
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient supplements (B vitamins and minerals) administered semi-blinded for the first year, double-blinded in crossover rotations during the second year, and open-label in the ensuing years.
Trial: 10802909
Drug: Nutrient supplements
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient supplements continued for at least 2 additional years after the 1-year double-blind phase.
Trial: 10802909
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of nutrient supplements after the 1-year double-blind phase.
Trial: 8816620
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist administered intranasally from day 1 of menstrual cycle
Trial: 8816620
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist administered intranasally from day 21 of menstrual cycle
Trial: 1574019
Drug: PVRV (Purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV (Purified Vero Rabies Vaccine)
Trial: 1574019
Drug: HDCV (Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV (Human Diploid Cell Vaccine)
Trial: 3998911
Drug: Holding room
RxNorm normalized name: dextromethorphan hydrobromide Oral Lozenge [Hold DM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holding room treatment
Trial: 26267817
Drug: Inactivated triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated triple influenza vaccine (TIV)
Trial: 26267817
Drug: Monovalent anti-A(H1N1)pdm09
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monovalent anti-A(H1N1)pdm09 vaccine
Trial: 17434401
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg raltegravir
Trial: 17434401
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg raltegravir
Trial: 17434401
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg raltegravir
Trial: 16130850
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of prophylactic antibiotics (administered for < 24 hours)
Trial: 7575822
Drug: Glycerin enema
RxNorm normalized name: glycerin Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerin enema (1 mL of glycerin mixed with 1 mL of warmed normal saline) within 30 minutes after birth and repeated at 12 hours of age
Trial: 31563272
Drug: Prolonged intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged intermittent theta burst stimulation (piTBS) monotherapy
Trial: 31563272
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) monotherapy
Trial: 28236956
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus a financial reward for each depot of medication received (€30 per month if fully compliant)
Trial: 26582851
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg p.o. before surgery and 75 mg twice daily in hospital and for 7 days after discharge
Trial: 21692760
Drug: Sugammadex dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 40%
Trial: 21692760
Drug: Sugammadex dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight
Trial: 21692760
Drug: Sugammadex dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 20%
Trial: 21692760
Drug: Sugammadex dosed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex dosed at 2 mg.kg(‐1) based on real body weight
Trial: 9863092
Drug: Kangke Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangke Injection (RSF)
Trial: 9863092
Drug: Glucose-insulin-potassium chloride
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium chloride (GIK)
Trial: 7887117
Drug: Inverse Sequence
RxNorm normalized name: Inversedine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverse Sequence Induction (ISI) with atracurium 0.6 mg.kg‐1 followed by thiopental 5 mg.kg‐1
Trial: 7887117
Drug: Rapid Sequence
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Sequence Induction (RSI) with succinylcholine (SUX) precurarized with atracurium 0.06 mg.kg‐1 followed by thiopental 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1
Trial: 2905148
Drug: Oxazepam 15
RxNorm normalized name: oxazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxazepam 15 mg (active control)
Trial: 2905148
Drug: Propranolol 40
RxNorm normalized name: propranolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg and 160 mg
Trial: 25758769
Drug: Saxagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (5 or 2.5 mg daily)
Trial: 19967572
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy including biofeedback tools (CBT-B)
Trial: 10812259
Drug: morphine, bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine, bolus 150 microg/kg + infusion 1 microg/kg per min and 0.5 microg/kg per min
Trial: 10812259
Drug: ketamine, bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine, bolus 60 microg/kg + infusion 6 microg/kg per min and 3 microg/kg per min
Trial: 27494516
Drug: Intra-articular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular glucocorticoid injections (IAGCIs)
Trial: 20979824
Drug: Docetaxel 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 37.5 mg/m² on days 1 and 8, oral capecitabine 950 mg/m² twice daily on days 1-14 (Group A)
Trial: 20979824
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² on days 1, oral capecitabine 950 mg/m² twice daily on days 1-14 (Group B)
Trial: 18570597
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg plus verapamil sustained release/trandolapril 180/2 mg
Trial: 18570597
Drug: Verapamil sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil sustained release/trandolapril 180/2 mg